

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Klaus BOSSLET et al.

Serial No. 09/302,434

Filed: April 30, 1999

For: BIFUNCTIONAL GLYCOPROTEINS HAVING A MODIFIED
CARBOHYDRATE COMPLEMENT AND THEIR USE IN TUMOR-
SELECTIVE THERAPY



Attorney Docket No. 38005-0039

Group Art Unit: 1644

Examiner: J. Hunt

RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

Reply under 37 C.F.R. § 1.116

Box AF

Commissioner for Patents

Washington, DC 20231

Sir:

This communication responds to the Final Office Action mailed February 11, 2002, in the captioned application. A response was due on May 11, 2002, which was a Saturday. Therefore, applicants respond on Monday, May 13, 2002 and believe that no fee is required. However, the Commissioner is authorized to credit any overpayment or charge any deficiency to Deposit Account No. 08-1641. Reconsideration and withdrawal of the outstanding rejections in view of the remarks set forth below are respectfully requested.

In the Claims:

Please cancel claims 22-36, 44, 45, 46, 48, 50 and 59-65 without prejudice or disclaimer.

Please amend the claims to read, as follows:

37. (Amended) A pharmaceutical kit comprising:
- (a) a first component comprising a bifunctional fusion glycoprotein or conjugate thereof comprising

Sub
E1